|
|
 |
|
Viewing report
|
|
|
|
Case Study: Sepsis - Xigris' Disappointing Performance Creates a Market Opportunity for Improved Sepsis Therapies
Datamonitor, May 2011, Pages: 36
Sepsis has high mortality levels; however, only few therapeutic strategies exist. The Surviving Sepsis Campaign (SSC) has helped to increase global awareness, standardize patient care, and reduce levels of mortality for sepsis. Negative clinical trial data have dented the commercial performance of Eli Lilly’s Xigris, creating an opportunity for improved sepsis therapeutics.
Features and benefits
- Profile and clinical and commercial evaluation of Eli Lilly’s Xigris (drotrecogin alfa [activated]).
- Review of unmet needs for sepsis and future challenges and opportunities in sepsis diagnosis and treatment.
- Overview of the Surviving Sepsis Campaign, including an evaluation of its impact on sepsis patient care.
Highlights
- Eli Lilly’s Xigris is currently the only marketed direct therapy for sepsis. However, its commercial performance has been disappointing, despite its market monopoly, due to negative results from clinical trials conducted post-approval. Upcoming results from the PROWESS-SHOCK trial are likely to be critical to the future success of the drug.
- There is a high unmet need for the identification and utilization of sepsis biomarkers that can identify those patients who would most likely benefit from new drugs and monitor patient response to therapies. However, current approaches lack the required predictive capability and reliability to be employed in clinical practice.
- The Surviving Sepsis Campaign (SSC) has proved successful in increasing global awareness of sepsis, standardizing patient care, and reducing patient mortality rates. However, the development of the SSC guidelines has been associated with controversy due to links with industry (particularly Eli Lilly).
Your key questions answered
- Understand the commercial and clinical attractiveness of Eli Lilly’s Xigris and the key reasons behind its disappointing commercial performance.
- Understand key unmet needs in sepsis and potential future developments in diagnosis and therapy.
- Gain insight into the Surviving Sepsis Campaign and its impact on sepsis management.
|
|
|
|
